Meeting: 2018 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5000 Authors: Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Lennart Astrom, et. al. Background: Docetaxel combined with androgen deprivation therapy (ADT) has improved survival in advanced prostate cancer (PCa). This randomized trial evaluates if six courses of docetaxel improves biochemical disease-free survival...
Pro zobrazení tohoto obsahu je třeba být přihlášen.